文献速递血液净化与透析

血液透析患者肌肉松弛剂使用:患病率、临床指征与不良结局

Muscle Relaxant Use Among Hemodialysis Patients: Prevalence, Clinical Indications, and Adverse Outcomes.
PubMed 文献 · Am J Kidney Dis · 2019-01-11

本研究基于美国肾脏数据系统2011年140,899例接受血液透析的Medicare参保成人,采用观察性队列设计分析肌肉松弛剂使用情况及其与不良结局的关联。结果显示10%患者使用肌肉松弛剂,使用与精神状态改变和跌倒风险升高相关,与骨折风险无显著关联,死亡风险降低可能源于残余混杂。

要点

  • 血透患者中10%使用肌肉松弛剂,与精神状态改变(HR 1.39)和跌倒(HR 1.18)风险升高相关。
  • 肌肉松弛剂使用与骨折风险无显著关联(HR 1.17;95%CI 0.98-1.39)。
  • 死亡风险降低(HR 0.85)可能为残余混杂,需谨慎解读。

核心结论

  • 肌肉松弛剂在血透患者中较常见,与精神状态改变和跌倒风险升高相关。
  • 无法排除肌肉松弛剂与骨折之间存在有临床意义的关联。
  • 死亡风险降低可能由残余混杂导致。

研究设计与样本

  • 观察性队列研究,纳入2011年美国肾脏数据系统中140,899例接受血液透析的Medicare参保成人。
  • 暴露为时变肌肉松弛剂使用,采用多变量Cox回归分析。

主要发现

  • 2011年10%患者使用肌肉松弛剂。
  • 11%发生精神状态改变,6%跌倒,3%骨折,13%死亡。
  • 肌肉松弛剂使用与精神状态改变风险升高相关(HR 1.39;95%CI 1.29-1.51)。
  • 肌肉松弛剂使用与跌倒风险升高相关(HR 1.18;95%CI 1.05-1.33)。
  • 肌肉松弛剂使用与骨折风险无显著关联(HR 1.17;95%CI 0.98-1.39)。

临床怎么用

  • 血透患者使用肌肉松弛剂时应警惕精神状态改变和跌倒风险。
  • 对使用肌肉松弛剂的血透患者应加强跌倒风险评估与预防。

局限性

  • 不能推断肌肉松弛剂使用与结局之间的因果关系。
  • 无法排除残余混杂。
  • 暴露和结局通过行政索赔数据确定。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

RATIONALE & OBJECTIVE: Muscle relaxants are often used to treat musculoskeletal pain or cramping, which are commonly experienced by hemodialysis patients. However, the extent to which muscle relaxants are prescribed in this population and the risks associated with their use have not been characterized. STUDY DESIGN: Observational cohort study. SETTING & PARTICIPANTS: 140,899 Medicare-covered adults receiving hemodialysis in 2011, identified in the US Renal Data System. EXPOSURE: Time-varying muscle relaxant exposure. OUTCOMES: Primary outcomes were time to first emergency department visit or hospitalization for altered mental status, fall, or fracture. Secondary outcomes were death and composites of death with each of the primary outcomes. ANALYTICAL APPROACH: Multivariable Cox regression analysis. RESULTS: 10% of patients received muscle relaxants in 2011. 11%, 6%, 3%, and 13% had an episode of altered mental status, fall, fracture, and death, respectively. Muscle relaxant use was associated with higher risk for altered mental status (HR, 1.39; 95% CI, 1.29-1.51) and fall (HR, 1.18; 95% CI, 1.05-1.33) compared to no use. Muscle relaxant use was not statistically significantly associated with higher risk for fracture (HR, 1.17; 95% CI, 0.98-1.39). Muscle relaxant use was associated with lower hazard of death (HR, 0.85; 95% CI, 0.76-0.94). However, hazards were higher for altered mental status or death (HR, 1.17; 95% CI, 1.10-1.25), fall or death (HR, 1.14; 95% CI, 1.06-1.22), and fracture or death (HR, 1.10; 95% CI, 1.01-1.20). LIMITATIONS: A causal association between muscle relaxant use and outcomes cannot be inferred, and residual confounding cannot be excluded. Exposure and outcomes were ascertained using administrative claims. CONCLUSIONS: Muscle relaxant use was common in hemodialysis patients and associated with altered mental status and falls. We could not rule out a clinically meaningful association between muscle relaxant use and fracture. The lower risk for death with muscle relaxants may have been the result of residual confounding. Future research to define the appropriate use of muscle relaxants in this population is warranted.

来源:Am J Kidney Dis,查看原文。版权归原作者所有。

引用

  1. Mina D, Johansen KL, McCulloch CE, et al. Muscle Relaxant Use Among Hemodialysis Patients: Prevalence, Clinical Indications, and Adverse Outcomes. Am J Kidney Dis. 2019. PMID: 30639233. doi:10.1053/j.ajkd.2018.11.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。